Seaport Therapeutics and Hemab Therapeutics have outlined plans for Nasdaq initial public offerings, adding to a growing slate of biotech listings in 2026, according to Pharmaceutical Technology. Seaport is offering 11.8 million shares priced between $16 and $18, while Hemab is offering 11.7 million shares in the same range. At the midpoint, Seaport expects net proceeds of approximately $183.5 million, while Hemab expects about $180.3 million.
Seaport, a neuropsychiatric biotech led by CEO Daphne Zohar, plans to allocate roughly $121 million of the IPO proceeds to advance GlyphAllo, an oral prodrug for major depressive disorder, through Phase IIb and into Phase III development. The treatment uses the company’s Glyph platform, which is designed to bypass the liver through the lymphatic system to improve bioavailability and reduce hepatotoxicity. Seaport has raised $325 million in financing to date, and Zohar previously co-founded Karuna, which Bristol Myers Squibb acquired for $14 billion in 2024.
Hemab plans to use about $120 million of its IPO proceeds to support clinical development of sutacimig, its bispecific antibody for bleeding disorders including Glanzmann thrombasthenia and Factor VII deficiency. The company also expects to allocate about $60 million toward HMB-002, a monovalent antibody in Phase I/II development for Von Willebrand Disease, along with new candidate discovery. Hemab reported $185.5 million in cash at the end of 2025 and has raised $347 million in financing rounds since 2021.
The planned listings come during a stronger year for biotech IPOs. Kailera Therapeutics raised $625 million earlier in April, while Eikon Therapeutics and Akis Oncology raised $381 million and $318 million, respectively, in January. Pharmaceutical Technology noted that IPO activity suggests the sector has maintained momentum despite macroeconomic uncertainty, though it remains unclear whether issuance will slow later in the year.
